Adjuvant melatonin for uveal melanoma (AMUM): protocol for a randomized open-label phase III study.

ABSTRACT:

Background

Uveal melanoma is the most common primary intraocular tumor in adults. In Sweden, at least 100 patients are diagnosed with the disease each year. Almost half of the patients develop metastases, with a median survival time of 1 year once metastases are detected. The primary ocular tumor is typically treated with either enucleation or brachytherapy, and no adjuvant treatment is added. Melatonin is an indolamine hormone that has improved survival in previous trials with patients diagnosed with various cancers, including advanced cutaneous melanoma. Side effects have been mild. We aim to investigate if adjuvant treatment with melatonin for 5 years following diagnosis of non-metastasized uveal melanoma can decrease the occurrence of metastases.

Methods

An open-label, p

SUBMITTER: Kal Omar R 

PROVIDER: S-EPMC10040135 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature